This article is for research and educational purposes only. Not medical advice.
Nicotinamide adenine dinucleotide (NAD+) is a coenzyme present in every living cell. It plays two fundamental roles: it is central to cellular energy metabolism via the electron transport chain, and it serves as the substrate for enzymes that regulate gene expression, DNA repair, and metabolic adaptation.
From a metabolic research perspective, NAD+ is interesting for a specific reason: it is the essential co-substrate for sirtuins — a family of enzymes (SIRT1-7) that regulate mitochondrial biogenesis, fat oxidation, glucose metabolism, and the cellular response to caloric restriction and exercise. Without adequate NAD+, sirtuin function is impaired. And sirtuin function is directly tied to how efficiently cells produce energy and oxidise fat.
NAD+ levels decline markedly with age. Studies in human blood and muscle tissue have found NAD+ levels in older adults are approximately 50% lower than in younger cohorts. Several mechanisms drive this decline:
This decline in NAD+ has downstream effects on sirtuin activity, mitochondrial function, and — relevant to metabolic health — fat oxidation capacity and insulin sensitivity.
The connection between NAD+ and fat metabolism runs through multiple pathways:
SIRT1 and fat oxidation. SIRT1 deacetylates PGC-1α — a master regulator of mitochondrial biogenesis and fatty acid oxidation. When NAD+ is abundant and SIRT1 is active, PGC-1α drives the formation of new mitochondria and upregulates fat oxidation pathways. When NAD+ declines, this signalling cascade slows. In animal models, restoring NAD+ via precursors has been shown to activate PGC-1α and increase fatty acid oxidation.
SIRT3 and mitochondrial function. SIRT3 is the primary mitochondrial sirtuin. It deacetylates and activates key enzymes in the mitochondrial electron transport chain and fat oxidation pathways. Adequate NAD+ supports SIRT3 activity, which in turn supports efficient energy extraction from fatty acids.
AMPK and the NAD+/NADH ratio. The ratio of NAD+ to NADH serves as a cellular energy sensor. A high NAD+/NADH ratio (indicating low energy availability) activates AMPK — the cellular "fuel gauge" that stimulates fat oxidation and inhibits fat storage. NAD+ precursor supplementation can favourably shift this ratio.
Because NAD+ itself is poorly absorbed orally, researchers have investigated precursor molecules:
Nicotinamide riboside (NR). Multiple Phase I and II human trials have confirmed oral NR supplementation (250–500 mg/day) raises whole-blood NAD+ levels in humans. A 2018 Nature Communications trial established this dose-response relationship.
Nicotinamide mononucleotide (NMN). A 2023 clinical trial by Imai et al. (Washington University) showed oral NMN (300 mg/day) increased NAD+ in skeletal muscle tissue — not just blood — in older adults, alongside measurable improvements in aerobic capacity and muscle function. This is notable as one of the first tissue-level NAD+ increases confirmed in humans.
A comprehensive review on NAD+ precursors and metabolic health is available on PubMed: Yoshino J et al. NAD+ Intermediates: The Biology and Therapeutic Potential of NMN and NR. Cell Metabolism 2018.
The honest answer from human clinical data: not directly, and not substantially. Current human trials of NR and NMN have not demonstrated significant weight reduction as a primary endpoint. The mechanisms that connect NAD+ to fat oxidation are real, but the magnitude of effect in humans at studied doses is insufficient to produce clinically meaningful weight loss on its own.
Where NAD+ research is more relevant:
For Australian researchers interested in NAD+ as a research compound, RetaLABS maintains a detailed NAD+ research guide covering current evidence and research applications.
Several rodent studies have shown NAD+ precursor supplementation improves insulin sensitivity — primarily through SIRT1-mediated improvements in glucose transporter expression and mitochondrial function. Human data in this area is limited but directionally consistent. For a broader look at how insulin sensitivity affects weight loss outcomes, the research on reversing insulin resistance through diet and lifestyle provides useful context.
The connection to insulin resistance is mechanistically clear: improved mitochondrial function and fat oxidation capacity reduce the ectopic fat accumulation (in muscle and liver) that is a primary driver of insulin resistance. Researchers should also note that intermittent fasting protocols independently activate SIRT1 and AMPK through overlapping nutrient-sensing pathways, making the two approaches potentially complementary for metabolic health.
For researchers studying NAD+ in a metabolic context:
NAD+ occupies a central and well-characterised role in cellular energy metabolism, fat oxidation, and the regulation of metabolic gene expression via sirtuins. The mechanisms connecting NAD+ to metabolic health are real and evidence-based. What the current human clinical data does not show is that supplementing NAD+ precursors produces direct, significant weight loss in humans. The compound's research value for metabolic health is more appropriately positioned around supporting mitochondrial function, insulin sensitivity, and the cellular environment within which other weight loss interventions operate — rather than as a standalone weight loss agent.
Eli Lilly's orforglipron is the first non-peptide oral GLP-1 agonist with full Phase 3 data. This guide covers the ATTAIN-1 obesity trial, the ACHIEVE-1 T2D trial, weight loss versus injectable semaglutide and tirzepatide, side-effect profile, and Australian timeline implications.
A detailed breakdown of the TRIUMPH-1 Phase 3 trial results for retatrutide — the triple-hormone agonist that achieved up to 28.3% mean weight loss at 80 weeks and ~30.3% in a higher-BMI subgroup at 104 weeks.
Is body recomposition possible? The evidence says yes — under specific conditions. Here's the science behind losing fat and gaining muscle at the same time, including protein targets, training requirements, and realistic timelines.